Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital
D. Boral Capital reissued their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a report issued on Wednesday,Benzinga reports. D. Boral Capital currently has a $12.00 price ...
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia
Quince Therapeutics (QNCX) “announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application ...
Business Wire4d
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...
Morningstar4d
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quarter of 2025 Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology ...
Business Wire7d
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...
Morningstar6d
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that ...
Investing7d
Quince Therapeutics secures USPTO nod for A-T treatment patent
SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...